We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.26 | 34.17 | 34.69 | 0.00 | 11:37:21 |
From Jun 2022 to Jun 2024
By Ian Walker
AstraZeneca PLC said Tuesday that initial results from a trial of datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small-cell lung cancer.
The pharmaceutical giant said that the trial showed encouraging efficacy and safety results that justify further studies.
Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.
"We look forward to continuing this important research with the goal of providing a new, effective treatment option for patients with advanced non-small-cell lung cancer," Astra's Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 09, 2022 06:34 ET (10:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
